PARP1 and cancer: Subsequently, olaparib was the first oral PARP inhibitor in phase II clinical trials, and monotherapy activity (400 mg b.i.d.)was demonstrated with acceptable tolerability in patients with advanced breast or ovarian cancers with BRCA-related cancer (Audeh et al, 2010; Tutt et al, 2010).